ORION CORPORATION: Annual Summary of Stock Exchange Releases published in 2009
ORION CORPORATION STOCK EXCHANGE RELEASE 20 JAN 2010 AT 12.30 EET
In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases published by the company in 2009. The releases are available on the internet website of Orion Corporation, at http://www.orion.fi/sereleases.
Orion points out that part of the information in the releases can have become out-dated.
Stock Exchange Releases in 2009
|
Jan 7th 2009 |
Orion's statutory negotiations completed. Personnel to be reduced by about 205 in Finland |
|
Jan 15th 2009 |
Orion sues Wockhardt USA LLC and Wockhardt Limited in the U.S. to enforce Orion's U.S. Patents covering its proprietary drug Stalevo® |
|
Jan 16th 2009 |
Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2008 |
|
Jan 19th 2009 |
Orion publishes 2008 Financial Statement release on 6 Feb 2009 |
|
Jan 28th 2009 |
Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation |
|
Feb 6th 2009 |
Orion Group Financial Review of 2008 |
|
Feb 6th 2009 |
Matters to be handled at the AGM of Orion Corporation on 23 March 2009 |
|
Feb 24th 2009 |
Orion: Primary objective of STRIDE-PD study was not achieved |
|
Mar 4th 2009 |
Orion Group Annual Report 2008 published |
|
Mar 5th 2009 |
Orion Corporation: Transfer of 44,806 own B-shares |
|
Mar 6th 2009 |
Orion withdraws EU application for extending the indication of Stalevo® |
|
Mar 23rd 2009 |
Orion Corporation: Decisions by the AGM on 23 March 2009 |
|
Mar 23rd 2009 |
Orion Corporation: Jukka Ylppö Vice Chairman of the Board of Directors. Compositions of Board committees |
|
Apr 14th 2009 |
Amendments to Orion's Articles of Association entered in the Trade Register |
|
Apr 20th 2009 |
Orion invites to a Q1 news conference on Monday 27 April 2009 |
|
Apr 27th 2009 |
Orion Group Interim Report 1-3/2009 |
|
Apr 29th 2009 |
Orion and Wockhardt settle patent dispute |
|
May 6 2009 |
Orion reacquires rights for i.v. levosimendan (Simdax®) |
|
Jun 10th 2009 |
Orion invites analysts and media to Q2 news conference on Friday 7 August 2009 |
|
Jul 31st 2009 |
Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States |
|
Aug 7th 2009 |
Orion Group Interim Report January-June 2009 |
|
Aug 7th 2009 |
Orion: Correction to English version of Interim Report 1-6/2009 |
|
Sep 4th 2009 |
Orion and Hospira,Inc. sue Sandoz companies in the U.S. to enforce their U.S. Patents covering the proprietary drug Precedex® |
|
Sep 21st 2009 |
Composition of the Nomination Committee of Orion Corporation |
|
Oct 6th 2009 |
Orion invites analysts and media to Q3 news conference on Monday 26 October 2009 |
|
Oct 21st 2009 |
Orion withdraws US application for extending the indication of Stalevo® |
|
Oct 26th 2009 |
Orion Corporation's publication schedules for financial reporting in 2010 |
|
Oct 26th 2009 |
Orion Group Interim Report January-September 2009 |
|
Nov 27th 2009 |
100,000 Orion A-shares converted into B-shares |
|
Dec 4th 2009 |
Orion clarifies information emanating from Capital Markets Day |
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2008 amounted to EUR 711 million. The Company invested EUR 90 million in research and development. At the end of 2008, the Group had a total of 3,300 employees, of whom 2,700 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.